Comparing SG&A Expenses: Johnson & Johnson vs Evotec SE Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals and biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two industry giants: Johnson & Johnson and Evotec SE, from 2014 to 2023.

Johnson & Johnson: A Steady Giant

Johnson & Johnson, a leader in healthcare, consistently reported SG&A expenses around $20 billion annually. Despite minor fluctuations, their expenses remained relatively stable, reflecting their robust market position and efficient cost management.

Evotec SE: A Rising Star

In contrast, Evotec SE, a prominent player in drug discovery, exhibited a remarkable growth trajectory. Their SG&A expenses surged by over 840% from 2014 to 2023, indicating aggressive expansion and investment in operational capabilities.

This comparison highlights the strategic differences between a well-established conglomerate and a rapidly growing biotech firm, offering insights into their financial strategies and market dynamics.